Table 1 Baseline characteristics
Variables | Median [IQR] or counts (%) |
|---|---|
Age—years | 59 [53–74] |
Male sex | 31 (76%) |
Charlson comorbidity index | 4 [3–8] |
Immunocompromised patients | 17 (41%) |
Body weight—kg | 65 [59–83] |
SAPS 2 at ICU admission | 48 [38–66] |
SOFA score at ICU admission | 7 [5–12] |
Length of ICU stay before inclusion - days | 10 [3–16] |
Patients without renal replacement therapy | 33 (80%) |
 Creatinine—µmol/L | 82 [52–129] |
 CCR—mL/min | 82 [43–90] |
 Patients with CCR ≥ 100 mL/min | 15/33 (45%) |
Patients under renal replacement therapy | 8 (20%) |
 Continuous renal replacement therapy | 8/8 (100%) |
 Ultrafiltration rate—mL/h | 2000 [1925–2300] |
 Blood flow rate—mL/min | 250 [250–250] |
Length of ICU stay before inclusion—days | 10 [3–16] |
SOFA score at inclusion | 8 [6–12] |
Sepsis at inclusion | 36 (88%) |
Septic shock at inclusion | 16 (39%) |
Organ support techniques at inclusion | |
 Invasive mechanical ventilation | 24 (59%) |
 Vasopressors | 22 (54%) |
 Renal replacement therapy | 8 (20%) |
 Extracorporeal membrane oxygenation | 3 (7%) |
Site(s) of infection with ESBL-PEa | |
 Respiratory tract | 35 (85%) |
 Urinary tract | 3 (7%) |
 Catheter related infection | 3 (7%) |
 Ascites infection | 1 (2%) |
 Bloodstream infection | 11 (27%) |
ESBL-PE speciesb | |
 Klebsiella pneumoniae | 25 (61%) |
 Escherichia coli | 14 (34%) |
 Klebsiella oxytoca | 2 (5%) |
 Citrobacter koseri | 1 (2%) |
Cefoxitin susceptibility | |
 Assessed by Vitek2 only | 30 (73%) |
 Assessed by E-test | 11 (27%) |
MIC for cefoxitin | |
 Vitek2 estimated MIC values (measured)—mg/L | |
   ≤ 4 mg/L | 36 (88%) |
   > 4 mg/L and ≤ 8 mg/L | 5 (12%) |
 E-test measured and imputed MICc values—mg/L | 3 [2–4] |
Probabilistic antibiotherapy before definitive cefoxitin treatment | 29 (71%) |
 Appropriate | 24/29 (83%) |
 Inappropriate | 5/29 (17%) |
Duration of probabilistic antibiotherapy—h | 48 [24–72] |
Cefoxitin loading dose administered—g | 41 (100%) |
 2 g | 39 (95%) |
 4 g | 2 (5%) |
Maintenance administration of cefoxitin | Â |
 Continuous | 39 (95%) |
 Intermittent | 2 (5%) |
Initial daily maintenance dose of cefoxitin—g | 6 [6–6] |
 2 g | 1 (2%) |
 3 g | 1 (2%) |
 4 g | 6 (15%) |
 6 g | 26 (64%) |
 8 g | 6 (15%) |
 12 g | 1 (2%) |
Duration of cefoxitin treatment—days | 5 [4–7] |